Cassava Sciences (SAVA) announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer, CMO. Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development of simufilam, Cassava’s investigational candidate for the treatment of Tuberous Sclerosis Complex-related epilepsy. Dr. Hulihan previously served as Chief Medical Officer at Marinus Pharmaceuticals
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA: